Argipressin tannate
As of the edition of 20 October 2026, Argipressin tannate is a protein: marketed, first approved in 2017 (CH); acts on AVPR1A, AVPR1B and AVPR2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2018
- Kind
- Protein
- Brand name
- Empressin
- First approved
- 20 June 2017 (CH)
- Approvals on record
- 3 in 3 regions
- Holder of the most recent approval
- Orpha-Devel Handels Und Vertriebs Gmbh; 3 holders in all
- Registered trials
- 2, 0 stopped early
- Disease areas
- Heart and blood vessels; Hormones; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 3 | 1 | 0 | 1 | 0 |
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 2 |